Green Tea in Crohn's Disease

NCT ID: NCT01231217

Last Updated: 2010-11-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess whether green tea or coffee influence the course and life quality of patients with mild to moderately active Crohn's disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Crohn's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

green (or white) tea

Patients are recommended to drink green (or white) tea but are not allowed to consume any coffee

Group Type OTHER

Green tea (Camellia sinensis)

Intervention Type OTHER

Patients are recommended to drink at least 5 cups of green tea per day

coffee

Patients are recommended to drink coffee but are not allowed to consume any tea

Group Type OTHER

Coffee

Intervention Type OTHER

Patients are recommended to drink as much coffee as they tolerate.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Green tea (Camellia sinensis)

Patients are recommended to drink at least 5 cups of green tea per day

Intervention Type OTHER

Coffee

Patients are recommended to drink as much coffee as they tolerate.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women and men ≥ 18 years with signed informed consent,
* Patients with proven Crohn's disease,
* Chronic-active course ≥ 3 months,
* Current CDAI ≥ 150 and ≤ 350,
* All medications for Crohn's disease have to be on a constant dosage for at least 4 weeks prior to study entry (i.e. 5-ASA, steroids),
* Ability of the participant to understand character and individual consequences of the study.

Exclusion Criteria

* Pregnancy or the wish to become pregnant, breastfeeding,
* Concomitant treatment with methotrexate, azathioprine or 6-mercaptopurine for \< 3 months,
* Treatment with TNF-alpha-antagonists, cyclosporine or tacrolimus \< 4 weeks prior to study entry,
* Participation in another study within the last 4 weeks,
* Ulcerative colitis or indeterminate colitis,
* Infectious colitis, including cytomegalovirus or Clostridium difficile induced colitis,
* Colitis for other reasons like known diverticulitis, radiation colitis, ischemic colitis or microscopic colitis,
* Malabsorption syndromes, lactose intolerance, celiac disease, exocrine pancreas insufficiency,
* Bleeding hemorrhoids,
* Other inflammatory or bleeding disorders of the colon and intestine, or diseases that may cause diarrhea or gastrointestinal bleeding,
* Intolerance / aversion to tea and/or coffee,
* Current treatment with antibiotics.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital Heidelberg

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Max Karner, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital Heidelberg

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Heidelberg

Heidelberg, , Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Anja Hanemann, MS

Role: CONTACT

Phone: 00496221568701

Email: [email protected]

Max Karner, MD

Role: CONTACT

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Anja Hanemann, MS

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GTCD-01

Identifier Type: -

Identifier Source: org_study_id